Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiles of ivosidenib-sensitive and ivosidenib-resistant IDH1-mutated murine bone marrow cells

ABSTRACT: To study the mechanism of resistance to ivosidenib, we developed a model of acquired drug resistance by treating ivosidenib-sensitive OCI-mIDH1/N cells continuously with ivosidenib in culture for a period of 2 months followed by a drug washout period. The resulting cell population (OCI-mIDH1/N-R cells) failed to differentiate upon ivosidenib treatment. We then performed RNA sequencing (RNA-seq) analysis of OCI-mIDH1/N and OCI-mIDH1/N-R cells.

ORGANISM(S): Mus musculus

PROVIDER: GSE217441 | GEO | 2022/11/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of SYK inhibition on gene expression during ivosidenib induced differentiation of IDH1-mutated murine bone marrow cells (OCI-mIDH1/N)

Project description:To investigate the mechanisms by which SYK inhibition sensitizes OCI-mIDH1/N cells to ivosidenib, we performed RNA sequencing (RNA-seq) analysis of cells treated with DMSO (vehicle control), ivosidenib alone, fostamatinib alone, entospletinib alone, or the combination of ivosidenib with each of the two SYK inhibitors for 9 days.

2022-11-08 | GSE217442 | GEO

Effect of SYK inhibition on gene expression during ivosidenib induced differentiation of IDH1-mutated murine bone marrow cells (OCI-mIDH1/N)

Project description:Effect of SYK inhibition on gene expression during ivosidenib induced differentiation of IDH1-mutated murine bone marrow cells (OCI-mIDH1/N)

| PRJNA899039 | ENA

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity (mouse_vivo_cgas_RT_rnaseq)

Project description:Isocitrate Dehydrogenase 1 (IDH1) is the most commonly mutated metabolic gene across human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of IDH1-mutant solid tumors is T cell exclusion, whereas mIDH1 inhibition in preclinical models restores anti-tumor immunity. Here, we define a cell-autonomous mechanism of mIDH1-driven immune evasion. IDH1-mutant solid tumors show striking, selective hypermethylation and silencing of the cytoplasmic dsDNA sensor, CGAS, compromising innate immune signaling. mIDH1 inhibition restores DNA demethylation, derepressing CGAS and transposable element (TE) subclasses. dsDNA produced by TE-reverse transcriptase activates cGAS, triggering viral mimicry and stimulating anti-tumor immunity. Thus, we demonstrate that mIDH1 epigenetically suppresses innate immunity and link endogenous reverse transcriptase activity to the mechanism of action of an FDA-approved oncology drug.

2024-04-30 | GSE266171 | GEO

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity [human_cgas_AZT_rnaseq]

2024-04-28 | GSE265804 | GEO

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity [mouse_glioma_rnaseq]

2024-04-28 | GSE264725 | GEO

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity [human_glioma_rnaseq]

2024-04-28 | GSE264723 | GEO